Early shift from ranibizumab to aflibercept for resistant pigment epitelial detachment in classical choroidal neovascularization
Küçük Resim Yok
Tarih
2017
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
International Journal of Ophthalmology (c/o Editorial Office)
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
AIM: To evaluate the therapeutic effect of aflibercept in patients with suboptimal response to ranibizumab therapy in the early period. METHOD: Thirty-eight patients with wet type age related macular degeneration(W-AMD) were involved in this study. Eighteen patients with suboptimal response were shifted to 3 doses monthly intravitreal aflibercept therapy (IVA) and left 20 patients with suboptimal response went on 3 more monthly intravitreal ranibizumab (IVR). All changes were evaluated with fluorescein anigography (FA) and optical coherence tomography (OCT). RESULTS: Preoperative mean visual acuity (VA) and central macular thickness (CMT) of patients were 0.84±0.47 logMAR and 360±84 ?m, respectively. One month after last IVR and IVA treatments, VA of patients were 1.1±0.34 (P=0.11) logMAR and 0.48±0.37 (P=0.019) logMAR and CMTs were 300±79 ?m (P=0.002) and 271±51 ?m (P=0.002), respectively. CONCLUSION: To eliminate repeated therapy for patients with suboptimal response to ranibizumab therapy, aflibercept might be a good alternative for early visual rehabilitation. Copyright 2017 by the IJO Press.
Açıklama
Anahtar Kelimeler
Aflibercept, Choroidal neovascularization, Early, Resistance, Suboptimal response, aflibercept, ranibizumab, adult, aged, Article, asthma, central macular thickness, clinical article, controlled study, drug efficacy, drug substitution, drug withdrawal, female, fluorescence angiography, human, male, optical coherence tomography, pigment epithelium, subretinal neovascularization, treatment outcome, treatment response, visual acuity, wet macular degeneration
Kaynak
International Eye Science
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
17
Sayı
10
